Xanthophyllomyces Yeast Pathway Engineering for Industrial Astaxanthin Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild-type strains of Xanthophyllomyces dendrorhous produce relatively low yields of astaxanthin, limiting their industrial competitiveness with synthetic production methods, which are cheaper but raise health and environmental concerns.
Innovation Solution
Modification of nucleotide sequences in Xanthophyllomyces dendrorhous to enhance astaxanthin production, including altering nucleotide sequences and amino acid sequences to improve yield and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type strains of X. dendrorhous are used for biological production of astaxanthin, then the production method is more natural and has higher antioxidant activity, but the yield is relatively low (200-400 μg/gDCW) which limits industrial competitiveness
Solution Approach 1:
The patent applies parameter changes by modifying nucleotide sequences in the yeast genome to alter metabolic parameters. Specifically, mutations in genes encoding enzymes of the mevalonate pathway and carotenoid biosynthesis pathway change the metabolic flux, leading to enhanced astaxanthin production while maintaining the biological production advantages.
Solution Approach 2:
The patent replaces the natural, unmodified biological system with a genetically modified system. By substituting the wild-type genetic machinery with modified nucleotide sequences, the invention achieves both the natural production benefits and enhanced yield through biochemical pathway optimization.
2Ease of manufacture
If synthetic production methods are used to produce astaxanthin, then the production cost is significantly lower (US$1,000 per kilogram), but health and safety concerns and environmental issues arise
Solution Approach 1:
The patent enables the yeast system to serve itself by endogenously producing astaxanthin through modified metabolic pathways. The genetically modified X. dendrorhous strain autonomously synthesizes high yields of astaxanthin using its own cellular machinery, eliminating the need for external chemical synthesis processes and their associated environmental hazards.
Solution Approach 2:
The patent introduces genetically modified yeast as an intermediary between synthetic chemistry and natural production. This biological intermediary converts simple carbon sources into astaxanthin through engineered metabolic pathways, providing a sustainable alternative that avoids direct chemical synthesis while maintaining economic viability.
3Adaptability or versatility
If wild-type strains of X. dendrorhous are used, then the yeast can assimilate a wide diversity of carbon sources, but the astaxanthin yield is limited to 200-400 μg/gDCW which is not industrially competitive
Solution Approach 1:
The patent changes the metabolic parameters of X. dendrorhous by modifying nucleotide sequences in genes controlling carbon metabolism and carotenoid synthesis. These genetic modifications alter the flux through metabolic pathways, enabling the yeast to redirect carbon from diverse carbon sources toward enhanced astaxanthin production while preserving substrate versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhanced astaxanthin yields up to industrially competitive levels are achieved, potentially reducing the cost and environmental impact of biological production.
Implementation Method 1
X. dendrorhous is a basidiomycetous yeast that produces AX as its main fermentation product using the mevalonate pathway
Implementation Method 2
X. dendrorhous is a basidiomycetous yeast that produces AX as its main fermentation product
Data Source
AI summary
An isolated nucleic acid associated with increased accumulation of astaxanthin derived from a Xanthophyllomyces dendrorhous strain. The isolated nucleic acid comprising nucleotide sequence set forth in SEQ ID NOs: 1240-12684 or a nucleotide sequence at least 80% identical thereto, or a fragment of the isolated nucleic acid, is provided, wherein the nucleotide sequence of the isolated nucleic acid is not identical to any one of the nucleotide sequences set forth in SEQ ID NOs: 12685-19331. Associated proteins, genetic construct, cells, and methods are also provided.